I'm not an investor but you already know my opinion from my due diligence, wheezing doesn't mean you are having an Asthma attack or even Asthma, that's why RSH are doing further clinical studies on how wheezing affect lung function and waiting for medical board approval to start.
Hence why I said the product has a small niche market, why do you think RSH did a failed T/O of ADR's IP which has a MC of only $30M and now RSH are developing Sorfe which supposedly will "complement" wheezo somehow.
Ann: Investor webinar and Q&A to be held Feb 23rd, page-3
-
- There are more pages in this discussion • 17 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
